ClinicalTrials.gg
RecruitingNCT07410494SELECT-CAR-NKUpdated Feb 18, 2026

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

A Phase 1/2 interventional study of EB-SELECT Single-Target CAR-NK Cells and Dual-Target Antigen-Selected CAR-NK in Cancer, Breast Cancer and Non-Small Cell Lung Cancer (NSCLC), sponsored by Essen Biotech. Recruiting at 1 site in China. Open to participants aged 8 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Essen Biotech · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
85
Allocation
Non-randomized
Ages
8 Years to 85 Years
Sex
All
01

Study summary

This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors. The CAR target antigen is selected for each participant after tumor profiling using a tissue biopsy and/or liquid biopsy. Participants will receive either a single-target or dual-target CAR-NK product based on the antigen profile.

Read the detailed description

This is an open-label, biomarker-driven adoptive cell therapy study.

Screening / Target Selection (Precision Step):

Participants undergo tumor antigen profiling using:

Tissue biopsy (preferred when safely feasible), and/or Liquid biopsy (e.g., circulating tumor DNA plus circulating tumor cells/exosome protein assay, as available in the platform).

Antigen profiling determines eligibility and assigns participants to:

Single-target CAR-NK if one antigen meets positivity thresholds, or Dual-target CAR-NK if two antigens meet thresholds or if heterogeneity is suspected.

Pre-specified target menu :

TROP2, Mesothelin (MSLN), B7-H3 (CD276), HER2, EGFR, GD2, Claudin18.2, GPC3, PSMA ("Target menu" can be expanded in amendments.)

Cell Source / Manufacturing Concept:

NK cells are obtained from a healthy allogeneic donor (unrelated or partially matched per site policy).

Donor NK cells are collected by leukapheresis, activated/expanded, and genetically modified to express:

a single CAR (Arm A) or a dual CAR / dual-target construct (Arm B). Final product is cryopreserved and released after sterility/identity/potency testing.

Conditioning \& Treatment:

Participants receive lymphodepleting chemotherapy followed by CAR-NK infusion(s). Many CAR-NK solid-tumor trials use conditioning regimens such as fludarabine and cyclophosphamide before infusion.

Optional cytokine support (e.g., low-dose IL-2) may be used per protocol to support NK persistence, consistent with approaches used in some CAR-NK studies.

Follow-up:

Intensive safety monitoring during the first 28 days. Tumor imaging at protocol-defined intervals. Correlative studies including CAR-NK persistence and ctDNA dynamics.

02

Conditions studied

  • Cancer
  • Breast Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (Locally Advanced or Metastatic)
  • Prostate Cancer - Recurrent
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Ovarian Cancer
  • Glioblastoma
  • Melanoma (Skin Cancer)
  • Acute Myeloid Leukemia (AML)
  • Non Hodgkin Lymphoma
  • Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
  • Liver Cancer

Keywords

  • CAR-NK
  • Solid tumor
  • Dual-target CAR
  • ctDNA
  • CAR-T
  • Breast cancer
  • Non-small cell lung cancer (NSCLC)
  • Colorectal cancer (CRC)
  • Prostate cancer
  • Pancreatic ductal adenocarcinoma (PDAC)
  • Ovarian, fallopian tube, and primary peritoneal cancers
  • Glioblastoma and other high-grade gliomas
  • Melanoma
  • Acute myeloid leukemia (AML)
  • Non-Hodgkin lymphoma (NHL), especially DLBCL and follicular lymphoma
  • Multiple myeloma (especially relapsed/refractory)
  • Liver cancer (hepatocellular carcinoma, HCC)
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 85 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Essen Biotech is the lead sponsor of 17 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years.
  • or cytologically confirmed advanced/unresectable or solid tumor that is after standard therapy, or no standard therapy available.
  • Targetable antigen positivity from the protocol target menu based on:

tissue and/or liquid biopsy platform (as defined in the lab manual).

  • Arm assignment rules :
  • Arm A: ≥1 antigen meets "positive" threshold
  • Arm B: ≥2 antigens meet "positive" threshold
  • performance status 0-1 (or 0-2 ).
  • At least one by 1.1.
  • Adequate organ function (hematologic, renal, hepatic, cardiac) within protocol-defined limits.
  • Willingness to undergo blood draws and required biopsies (when medically feasible).
  • Negative pregnancy test for participants of ; agreement to effective during and after study treatment.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within a defined .
  • Active, uncontrolled infection requiring IV antibiotics; known uncontrolled ; active / with detectable viral load (per local policy).
  • Active requiring escalating or urgent intervention (stable treated CNS disease may be allowed ).
  • Active disease requiring systemic , or chronic systemic steroids above protocol threshold.
  • cardiovascular disease (e.g., recent MI, unstable arrhythmia), uncontrolled pulmonary disease, or other serious comorbidity that increases risk.
  • Major surgery or anticancer therapy too close to lymphodepletion (protocol-defined washout).
  • Pregnant or breastfeeding.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    Single-Target Antigen-Selected CAR-NK

    Participants whose profiling identifies one dominant actionable antigen.

    Biological: EB-SELECT Single-Target CAR-NK Cells

  • Experimental
    Dual-Target Antigen-Selected CAR-NK

    Participants whose profiling identifies two actionable antigens, or strong evidence of antigen heterogeneity.

    Biological: Dual-Target Antigen-Selected CAR-NK

Interventions

  • BiologicalFludarabineStudies of FludarabineFludarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Donor-derived CAR-NK cells expressing a single CAR selected from the target menu. WITH Fludarabine (IV) + Cyclophosphamide (IV), administered prior to CAR-NK infusion. Similar conditioning drugs are used in CAR-NK solid tumor trials.

    Also known as: Lymphodepleting Chemotherapy, Fludarabine, Cyclophosphamide, IL-2

  • BiologicalFludarabineStudies of FludarabineFludarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants whose profiling identifies two actionable antigens, or strong evidence of antigen heterogeneity. WITH Fludarabine (IV) + Cyclophosphamide (IV), administered prior to CAR-NK infusion . Similar conditioning drugs are used in CAR-NK solid tumor trials.

    Also known as: EB-SELECT Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide, IL-2

06

What researchers measure

Primary outcomes

  1. Incidence, type, and severity of adverse events (AEs), graded by CTCAE v5.0

    Time frame: 28 DAYS

  2. Incidence of Dose-Limiting Toxicities (DLTs)

    Time frame: 28 DAYS

Secondary outcomes

  1. Objective Response Rate (ORR) (RECIST 1.1)

    Time frame: 12 months

  2. Disease Control Rate (DCR)

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

Of 102 non-industry phase 1/2 interventional studies under Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 111. This study's planned 22 months is below that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2026
First posted
Feb 13, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Dec 28, 2027
CompletionEst.
Dec 28, 2028
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07410494
Lead sponsor
Essen Biotech
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Feb 1, 2026
Primary completion
Dec 28, 2027 (estimated)
Completion
Dec 28, 2028 (estimated)
Last update
Feb 18, 2026

Study contacts

Rhoda M Smith, PHD
Contact
clinical-trials@essen-biotech.com
+12077706670

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fludarabine

Start the discussion